Assembly Biosciences, Inc.
ASMBAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 1, 2026 | Mizuho Securities | Salim Syed | $53.00(+58%) | $33.63 | TheFly |
| Sep 1, 2026 | UBS | Ashwani Verma | $52.00(+55%) | $33.63 | StreetInsider |
| Aug 18, 2026 | H.C. Wainwright | Patrick Trucchio | $50.00(+67%) | $30.01 | StreetInsider |
| Jun 15, 2026 | Mizuho Securities | $45.00(+96%) | $22.96 | TheFly | |
| Nov 20, 2025 | Mizuho Securities | Salim Syed | $40.00(+3%) | $39.00 | TheFly |
| Sep 24, 2025 | JMP Securities | Roy Buchanan | $38.00(+47%) | $25.90 | TheFly |
| Sep 24, 2024 | Mizuho Securities | Salim Syed | $36.00(+121%) | $16.26 | StreetInsider |
| Sep 20, 2024 | Jefferies | Dennis Ding | $35.00(+89%) | $18.50 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| UBS | maintain | Buy | Nov 3, 2026 |
| Mizuho | maintain | Outperform | Sep 1, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 18, 2026 |
| Mizuho | maintain | Outperform | Jun 15, 2026 |
| Guggenheim | maintain | Buy | May 28, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 4, 2026 |
| Guggenheim | maintain | Buy | Apr 6, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 26, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 22, 2025 |
| Mizuho | maintain | Outperform | Nov 20, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 14, 2025 |
| Guggenheim | maintain | Buy | Sep 8, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Mar 24, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Dec 27, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Mar 23, 2023 |
| Mizuho | maintain | Buy | Nov 15, 2022 |
| Truist Securities | downgrade | Buy →Hold | Oct 23, 2022 |
| Truist Securities | maintain | Buy | Mar 31, 2022 |
| HC Wainwright & Co. | maintain | Neutral | Sep 13, 2021 |
| William Blair | downgrade | Outperform →Market Perform | Sep 1, 2021 |
| SVB Leerink | maintain | Market Perform | May 9, 2021 |
| SVB Leerink | downgrade | Outperform →Market Perform | Mar 22, 2021 |
| Jefferies | downgrade | Buy →Hold | Nov 5, 2020 |
| Truist Securities | maintain | Buy | Oct 19, 2020 |
| SVB Leerink | maintain | Outperform | Jul 7, 2020 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.20 | $-0.72 | $13.4M | $8.6M |
| May 7, 2026 | $-0.54 | $-0.73 | $8.2M | $9.3M |
| Mar 19, 2026 | $2.48 | $-0.51 | $42.5M | $7.4M |
| Nov 10, 2025 | $-0.72 | $-0.50 | $10.8M | $7.5M |
| Aug 6, 2025 | $-1.33 | $-0.65 | $9.6M | $9.3M |
| May 8, 2025 | $-1.17 | $-2.01 | $9.4M | $7.4M |
| Mar 20, 2025 | $-1.57 | $-1.75 | $7.4M | $3.5M |
| Nov 7, 2024 | $-1.51 | $-2.02 | $6.8M | $7.0M |
News
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present and participate in one-on-one meetings at the following upcoming investor conferences in November:
– Phase 2 study will evaluate the safety, pharmacokinetics and antiviral activity of ABI-6250 in participants with chronic HDV infection – – Initial data from the Phase 2 study is expected in the fourth quarter of 2027 –
Assembly Biosciences (NASDAQ: ASMB - Get Free Report) and RYTHM (NASDAQ: RYM - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends. Profitability This table compares Assembly Biosciences and RYTHM's
ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction
MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.
MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.
COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –
The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Assembly Biosciences, Inc. (ASMB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ASMB's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.
Assembly Biosciences (ASMB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
LQDT, IA and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 25th, 2026.
IA, ASMB, LQDT, OFG and TGT have been added to the Zacks Rank #1 (Strong Buy) List on August 25th, 2026.
LITE, ONTO and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 21st, 2026.
MCY, ASMB, ONTO, BSET and UNH have been added to the Zacks Rank #1 (Strong Buy) List on August 21st, 2026.
Does Assembly Biosciences (ASMB) have what it takes to be a top stock pick for momentum investors? Let's find out.
The average of price targets set by Wall Street analysts indicates a potential upside of 40.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Assembly Biosciences is maintained at a 'Buy' rating, driven by pipeline advancement and a strong cash position. Key catalysts include phase 2 trials for GS-1179 in genital herpes and ABI-6250 in chronic HDV, PBC, and PSC, with multiple readouts expected 2027–2028. ASMB's partnership with Gilead on GS-1179 offers strategic optionality between milestone/royalty payments or a 40% cost-profit share.